- Submitted Biologics License Application (BLA) to US FDA for Viaskin Peanut Patch (ages 4-7) with Priority Review requested.
- Q3 2026 net loss widened to $64.5M vs $33.2M prior year due to ramped commercial readiness costs.
- Q3 EPS stood at -$0.14 compared to -$0.24 in Q3 2025.
?? Positive AI Sentiment (+3.0 / 10)